Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Thomas Schmitt-Mechelke is active.

Publication


Featured researches published by Thomas Schmitt-Mechelke.


American Journal of Human Genetics | 2009

Infection-Triggered Familial or Recurrent Cases of Acute Necrotizing Encephalopathy Caused by Mutations in a Component of the Nuclear Pore, RANBP2

Derek E. Neilson; Mark D. Adams; Caitlin M D Orr; Deborah K. Schelling; Robert M. Eiben; Douglas S. Kerr; Jane E. Anderson; Alexander G. Bassuk; Ann M. E. Bye; Anne Marie Childs; Antonia Clarke; Yanick J. Crow; Maja Di Rocco; Christian Dohna-Schwake; Gregor Dueckers; Alfonso Fasano; Artemis D. Gika; Dimitris Gionnis; Mark P. Gorman; Padraic J. Grattan-Smith; Annette Hackenberg; Alice Kuster; Markus G. Lentschig; Eduardo Lopez-Laso; Elysa J. Marco; Sotiria Mastroyianni; Julie Perrier; Thomas Schmitt-Mechelke; Serenella Servidei; Angeliki Skardoutsou

Acute necrotizing encephalopathy (ANE) is a rapidly progressive encephalopathy that can occur in otherwise healthy children after common viral infections such as influenza and parainfluenza. Most ANE is sporadic and nonrecurrent (isolated ANE). However, we identified a 7 Mb interval containing a susceptibility locus (ANE1) in a family segregating recurrent ANE as an incompletely penetrant, autosomal-dominant trait. We now report that all affected individuals and obligate carriers in this family are heterozygous for a missense mutation (c.1880C-->T, p.Thr585Met) in the gene encoding the nuclear pore protein Ran Binding Protein 2 (RANBP2). To determine whether this mutation is the susceptibility allele, we screened controls and other patients with ANE who are unrelated to the index family. Patients from 9 of 15 additional kindreds with familial or recurrent ANE had the identical mutation. It arose de novo in two families and independently in several other families. Two other patients with familial ANE had different RANBP2 missense mutations that altered conserved residues. None of the three RANBP2 missense mutations were found in 19 patients with isolated ANE or in unaffected controls. We conclude that missense mutations in RANBP2 are susceptibility alleles for familial and recurrent cases of ANE.


Brain | 2017

Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders

Markus Wolff; Katrine Johannesen; Ulrike B. S. Hedrich; Silvia Masnada; Guido Rubboli; Elena Gardella; Gaetan Lesca; Dorothée Ville; Mathieu Milh; Laurent Villard; Alexandra Afenjar; Sandra Chantot-Bastaraud; Cyril Mignot; Caroline Lardennois; Caroline Nava; Niklas Schwarz; Marion Gerard; Laurence Perrin; Diane Doummar; Stéphane Auvin; Maria J Miranda; Maja Hempel; Eva H. Brilstra; N.V.A.M. Knoers; Nienke E. Verbeek; Marjan van Kempen; Kees P. J. Braun; Grazia M.S. Mancini; Saskia Biskup; Konstanze Hörtnagel

Mutations in SCN2A, a gene encoding the voltage-gated sodium channel Nav1.2, have been associated with a spectrum of epilepsies and neurodevelopmental disorders. Here, we report the phenotypes of 71 patients and review 130 previously reported patients. We found that (i) encephalopathies with infantile/childhood onset epilepsies (≥3 months of age) occur almost as often as those with an early infantile onset (<3 months), and are thus more frequent than previously reported; (ii) distinct phenotypes can be seen within the late onset group, including myoclonic-atonic epilepsy (two patients), Lennox-Gastaut not emerging from West syndrome (two patients), and focal epilepsies with an electrical status epilepticus during slow sleep-like EEG pattern (six patients); and (iii) West syndrome constitutes a common phenotype with a major recurring mutation (p.Arg853Gln: two new and four previously reported children). Other known phenotypes include Ohtahara syndrome, epilepsy of infancy with migrating focal seizures, and intellectual disability or autism without epilepsy. To assess the response to antiepileptic therapy, we retrospectively reviewed the treatment regimen and the course of the epilepsy in 66 patients for which well-documented medical information was available. We find that the use of sodium channel blockers was often associated with clinically relevant seizure reduction or seizure freedom in children with early infantile epilepsies (<3 months), whereas other antiepileptic drugs were less effective. In contrast, sodium channel blockers were rarely effective in epilepsies with later onset (≥3 months) and sometimes induced seizure worsening. Regarding the genetic findings, truncating mutations were exclusively seen in patients with late onset epilepsies and lack of response to sodium channel blockers. Functional characterization of four selected missense mutations using whole cell patch-clamping in tsA201 cells-together with data from the literature-suggest that mutations associated with early infantile epilepsy result in increased sodium channel activity with gain-of-function, characterized by slowing of fast inactivation, acceleration of its recovery or increased persistent sodium current. Further, a good response to sodium channel blockers clinically was found to be associated with a relatively small gain-of-function. In contrast, mutations in patients with late-onset forms and an insufficient response to sodium channel blockers were associated with loss-of-function effects, including a depolarizing shift of voltage-dependent activation or a hyperpolarizing shift of channel availability (steady-state inactivation). Our clinical and experimental data suggest a correlation between age at disease onset, response to sodium channel blockers and the functional properties of mutations in children with SCN2A-related epilepsy.


Pediatrics | 2015

Incidence and Outcomes of Symptomatic Neonatal Arterial Ischemic Stroke

Sebastian Grunt; Lea Mazenauer; Sarah E. Buerki; Eugen Boltshauser; Andrea Capone Mori; Alexandre N. Datta; Joel Victor Fluss; Danielle Mercati; Elmar Keller; Oliver Maier; Claudia Poloni; Gian-Paolo Ramelli; Thomas Schmitt-Mechelke; Maja Steinlin

BACKGROUND AND OBJECTIVES: Neonatal arterial ischemic stroke (NAIS) is associated with considerable lifetime burdens such as cerebral palsy, epilepsy, and cognitive impairment. Prospective epidemiologic studies that include outcome assessments are scarce. This study aimed to provide information on the epidemiology, clinical manifestations, infarct characteristics, associated clinical variables, treatment strategies, and outcomes of NAIS in a prospective, population-based cohort of Swiss children. METHODS: This prospective study evaluated the epidemiology, clinical manifestations, vascular territories, associated clinical variables, and treatment of all full-term neonates diagnosed with NAIS and born in Switzerland between 2000 and 2010. Follow-up was performed 2 years (mean 23.3 months, SD 4.3 months) after birth. RESULTS: One hundred neonates (67 boys) had a diagnosis of NAIS. The NAIS incidence in Switzerland during this time was 13 (95% confidence interval [CI], 11–17) per 100 000 live births. Seizures were the most common symptom (95%). Eighty-one percent had unilateral (80% left-sided) and 19% had bilateral lesions. Risk factors included maternal risk conditions (32%), birth complications (68%), and neonatal comorbidities (54%). Antithrombotic and antiplatelet therapy use was low (17%). No serious side effects were reported. Two years after birth, 39% were diagnosed with cerebral palsy and 31% had delayed mental performance. CONCLUSIONS: NAIS in Switzerland shows a similar incidence as other population-based studies. About one-third of patients developed cerebral palsy or showed delayed mental performance 2 years after birth, and children with normal mental performance may still develop deficits later in life.


Epilepsia | 2010

A case of SUDEP in a patient with Dravet syndrome with SCN1A mutation

François Le Gal; Christian Korff; Christine Monso-Hinard; Michael T. Mund; Michael A. Morris; Alain Malafosse; Thomas Schmitt-Mechelke

A boy with a clinical history of pharmacologically resistant Dravet syndrome died suddenly after falling asleep. The autopsy concluded that the cause of death was sudden unexpected death in epilepsy (SUDEP). Postmortem molecular analysis of the SCN1A gene by multiplex ligation‐dependent probe amplification (MLPA), high‐resolution melting curve analysis (HRMCA), and sequencing revealed a frameshift duplication of adenosine at position 504. The incidence of this mutation is discussed as a potential cause of SUDEP.


Developmental Medicine & Child Neurology | 2010

Cerebral sinus venous thrombosis in Swiss children

Sebastian Grunt; Kevin Wingeier; Edith Wehrli; Eugen Boltshauser; Andrea Capone; Joel Victor Fluss; Danielle Gubser-Mercati; Pierre-Yves Jeannet; Elmar Keller; Jean-Pierre Marcoz; Thomas Schmitt-Mechelke; Peter Weber; Markus Weissert; Maja Steinlin

Aim  To describe the characteristics of paediatric cerebral sinus venous thrombosis (CSVT) in Switzerland.


Neurology | 2014

Factors affecting cognitive outcome in early pediatric stroke

Martina Studer; Eugen Boltshauser; Andrea Capone Mori; Alexandre N. Datta; Joel Victor Fluss; Danielle Mercati; Annette Hackenberg; Elmar Keller; Oliver Maier; Jean-Pierre Marcoz; Gian-Paolo Ramelli; Claudia Poloni; Regula Schmid; Thomas Schmitt-Mechelke; Edith Wehrli; Theda Heinks; Maja Steinlin

Objective: We examined cognitive performance in children after stroke to study the influence of age at stroke, seizures, lesion characteristics, neurologic impairment (NI), and functional outcome on cognitive outcome. Methods: This was a prospectively designed study conducted in 99 children who sustained an arterial ischemic stroke (AIS) between the age of 1 month and 16 years. All children underwent cognitive and neurologic follow-up examination sessions 2 years after the insult. Cognitive development was assessed with age-appropriate instruments. Results: Although mean cognitive performance was in the lower normative range, we found poorer results in subtests measuring visuoconstructive skills, short-term memory, and processing speed. Risk factors for negative cognitive outcome were young age at stroke, seizures, combined lesion location (cortical and subcortical), as well as marked NI. Conclusions: We recommend that all children with a history of AIS undergo regularly scheduled neuropsychological assessment to ensure implementation of appropriate interventions and environmental adjustments as early as possible.


Epilepsia | 2014

Co-occurring malformations of cortical development and SCN1A gene mutations

Carmen Barba; Elena Parrini; Roland Coras; Anna Galuppi; Dana Craiu; Gerhard Kluger; Antonia Parmeggiani; Tom Pieper; Thomas Schmitt-Mechelke; Pasquale Striano; Flavio Giordano; Ingmar Blümcke; Renzo Guerrini

To report on six patients with SCN1A mutations and malformations of cortical development (MCDs) and describe their clinical course, genetic findings, and electrographic, imaging, and neuropathologic features.


Epilepsia | 2012

Attention-deficit/hyperactivity disorder in childhood epilepsy: a neuropsychological and functional imaging study

Nina Bechtel; Maja Kobel; Iris-Katharina Penner; Karsten Specht; Markus Klarhöfer; Klaus Scheffler; Klaus Opwis; Thomas Schmitt-Mechelke; Andrea Capone; Peter Weber

Purpose:  Children with epilepsy have a significant risk for attention‐deficit/hyperactivity disorder (ADHD), which is often accompanied by deficits in working memory performance. However, it is not yet clear whether there are specific differences in the underlying mechanisms of working memory capability between children with epilepsy‐related ADHD and those with developmental ADHD. There is evidence that methylphenidate can improve the behavioral difficulties in children with developmental ADHD. Whether this medication has the same effect on ADHD symptoms in patients with epilepsy is not yet well understood. The aim of the present study is, therefore, to evaluate whether boys with epilepsy‐related ADHD and developmental ADHD share a common behavioral, pharmacoresponsive, and neurofunctional pathophysiology.


American Journal of Medical Genetics Part A | 2011

The Male Phenotype in Osteopathia Striata Congenita With Cranial Sclerosis

Sarah K. Holman; Phil Daniel; Zandra A. Jenkins; Rachel L. Herron; Timothy R. Morgan; Ravi Savarirayan; C. W. Chow; Axel Bohring; Annette Mosel; Didier Lacombe; Bernhard Steiner; Thomas Schmitt-Mechelke; Barbara Schröter; Annick Raas-Rothschild; Sixto Garcia Miñaur; Mary Porteous; Michael J. Parker; Oliver Quarrell; Dagmar Tapon; Valérie Cormier-Daire; Sahar Mansour; Ruth Nash; Laurence A. Bindoff; Torunn Fiskerstrand; Stephen P. Robertson

Osteopathia striata with cranial sclerosis (OSCS) is an X‐linked disease caused by truncating mutations in WTX. Females exhibit sclerotic striations on the long bones, cranial sclerosis, and craniofacial dysmorphism. Males with OSCS have significant skeletal sclerosis, do not have striations but do display a more severe phenotype commonly associated with gross structural malformations, patterning defects, and significant pre‐ and postnatal lethality. The recent description of mutations in WTX underlying OSCS has led to the identification of a milder, survivable phenotype in males. Individuals with this presentation can have, in addition to skeletal sclerosis, Hirschsprung disease, joint contractures, cardiomyopathy, and neuromuscular anomalies. A diagnosis of OSCS should be considered in males with macrocephaly, skeletal sclerosis that is most marked in the cranium and the absence of metaphyseal striations. The observation of striations in males may be indicative of a WTX mutation in a mosaic state supporting the contention that this sign in females is indicative of the differential lyonization of cells in the osteoblastic lineage.


Developmental Medicine & Child Neurology | 2013

Basilar artery stroke in childhood

Barbara Goeggel Simonetti; Barbara Ritter; Matthias Gautschi; Edith Wehrli; Eugen Boltshauser; Thomas Schmitt-Mechelke; Peter Weber; Markus Weissert; Marwan El-Koussy; Maja Steinlin

Aim  Little is known about basilar artery stroke (BAS) in children. The objective of this study was to calculate the incidence of BAS in children and to analyse the clinical presentation, risk factors, radiological findings, therapeutic approaches, and outcome of BAS in childhood.

Collaboration


Dive into the Thomas Schmitt-Mechelke's collaboration.

Top Co-Authors

Avatar

Eugen Boltshauser

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Maja Steinlin

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Elmar Keller

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Markus Weissert

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Danielle Mercati

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joel Victor Fluss

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge